The global Sarcopenia Treatment market is estimated to be $3.2 billion in 2023 and is poised to register 7.04% growth over the forecast period from 2023 to 2030.
Key driving factors including chronic diseases and conditions on the rise, increasing geriatric population, strong growth in online sales, focus on emerging countries as a major marketing strategy for expansion, and increasing global Healthcare Expenditure worldwide is among the main market drivers. On the other hand, challenges such as lack of pharmaceutical interventions for sarcopenia treatment, and high costs of supplements restrict the market growth.
Sarcopenia Treatment Market Analysis
Sarcopenia is a condition characterized by age-related loss of skeletal muscle mass and strength. It affects around 30% of adults over the age of 60 and around 50% of the population aged over the age of 80. Progress of sarcopenia leads to loss of mobility, an increased risk of falls and fractures, and an increased risk of developing other disabling chronic conditions. Currently, there are no viable pharmaceutical interventions to slow the progression of Sarcopenia.
The development of Sarcopenia can be caused by several factors including age-related changes, lifestyle factors, and chronic diseases. Age-related factors include lower hormone levels, cellular changes, a decline in the ability to convert protein to muscle, lifestyle factors including inactivity and lack of exercise, prolonged bed rest, Loss of mobility, Low protein and calorie intake, Dental, and oral problems, and other factors.
In addition to physical limitations, patients with sarcopenia experience emotional impacts such as fear of injury and embarrassment of their physical limitations, limited social interactions and feelings of isolation, and difficulties caring for themselves and living independently.
In addition, chronic conditions can result in the development of sarcopenia. Proper nutrition and resistance exercise are currently recommended strategies to prevent and slow the progression of sarcopenia.
Market Dynamics
Market Trend- Chronic diseases and conditions are on the rise
Muscle loss is associated with several metabolic, physiologic, and psychological/cognitive pathologies. Chronic conditions such as bone and joint diseases, metabolic disorders, endocrine diseases, liver and kidney disorders, cancer, malnourishment, cardiovascular disease, dementia, and others can result in the development of sarcopenia.
Chronic diseases and conditions are on the rise worldwide driven by an aging population, growing middle class, rapid urbanization, and sedentary lifestyles. According to the World Health Organization, chronic diseases are the cause of death of 41 million people each year, equivalent to 71% of all deaths globally. Chronic conditions including cardiovascular diseases, kidney disorders, diabetes, neurological conditions, and others are rapidly expanding among the population.
For instance, CDC identifies that about 659,000 people in the United States die from heart disease each year. The WHO identifies cardiovascular diseases account for 17.9 million deaths, followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). The increasing chronic conditions result in the increasing prevalence of sarcopenia, driving up the need for safe and efficient treatment options.
Market Driver- Strong growth in online sales
Vitamins, proteins, and other supplements are marketed aggressively through online channels, targeted marketing efforts, and promotion through social media and other online portals. However, challenges related to products, inadequate knowledge, presence of a large number of brands restrain the supplements market growth. Companies are working on providing nutritional information, regulatory approvals, and other information through chatbots, motivation messages, and programs to market supplements for sarcopenia. Further, companies are using testimonials to attract customer confidence.
Market Opportunity- Focus on emerging countries remains a major marketing strategy for expansion
Increasing patient population, reimbursement systems, growing awareness, and expansion plans of leading companies are encouraging leading supplement providers to expand their operations in developing countries, which account for 75% of the world's population.
Increasing household income levels, growing medical tourism, and improved healthcare infrastructure in the Asia Pacific and Latin American regions are encouraging protein, vitamins, calcium, and other supplements to expand their products in emerging countries.
Over the forecast period, the market growth (CAGR) of the Asia Pacific and Latin America regions is estimated at 7.3% and 7.2% respectively, as compared to the global average of 7.04%. On the other hand, limited public awareness, and lack of treatment options restrain market growth in these markets.
Market Segmentation
The global Sarcopenia Treatment Market is segmented into Types, Sales Channels, and Countries.
Protein supplements dominated the market with a 45.8% market share in 2022
Protein supplements, in particular, comprising essential amino acids play an important role in the improvement of muscle protein synthesis when taken in addition to resistance exercise. Though protein intake can boost muscle protein in individuals, the creation of these muscle proteins is diminished in the geriatric population. Accordingly, resistance exercise coupled with protein intake is widely suggested by physicians for diverse age groups.
Resistance-training programs improve lean body mass, muscle fiber size, muscle strength, and physical function in older adults. A wide range of resistance exercises including free weights, machines, body weights, or elastic bands is suggested for muscle development.
Sarcopenia is considered a muscle disease, characterized by muscle failure or insufficiency. Different needs for protein doses exist in young and elderly individuals, suggesting intake of high-quality protein intake with each meal in varying quantities for increased strength and physical performance.
Online Pharmacies segment is growing at the highest CAGR during the forecast period
Rapid internet penetration, e-healthcare initiatives, increase in healthcare insurance, growing chronic conditions, self-medication, geriatric population preference for home delivery, and other factors are encouraging sales through online pharmacies.
In addition, discount offers, information on various products, and others drive sales through online pharmacies. However, challenges related to false claims, counterfeit products, and others pose risks for companies marketing protein, vitamin, and mineral supplements.
By Region, North America accounts for the highest market size for the period 2023 to 2030
North America, generated the highest revenue from Sarcopenia Treatment in 2022. The regional market is well established and the introduction of new products from leading companies supports the market potential.
United States- The US has the world’s largest pharmaceutical market with around $400 billion in sales. Of this, OTC remains a robust segment driven by sales in mass merchandisers, drug stores, food stores, gas stations, and other retail stores. Further, online e-commerce and teleshopping also support the sales of supplements in the country.
The country’s sarcopenia treatment market is forecast to grow at a rapid pace driven by increasing health consciousness and supplement availability across distribution channels. Due to the spread of coronavirus, the demand for protein and vitamin supplements was widely observed to reduce potential symptoms at home. However, relatively high penetration rates and intense competitive conditions lower the prospects for market expansion.
The presence of various key players that are involved in the supply of supplements in various forms is expected to lead the market growth and increase the potential of production to meet the supply demand. Highly sophisticated marketing campaigns and distribution through numerous sales channels to cater to the self-medication trends of customers are observed in the US.
Segmentation
By Type
By Sales Channel
By Region
Key Players
Leading companies profiled in the study include-
Sarcopenia Treatment Market Outlook 2023
1 Market Overview
1.1 Introduction to Sarcopenia Treatment Market
1.2 Scope of the Study
1.3 Research Objective
1.3.1 Key Market Scope and Segments
1.3.2 Players Covered
1.3.3 Years Considered
2 Executive Summary
2.1 2023 Sarcopenia Treatment Industry- Market Statistics
3 Market Dynamics
3.1 Market Drivers
3.2 Market Challenges
3.3 Market Opportunities
3.4 Market Trends
4 Market Factor Analysis
4.1 Porter’s Five Forces
4.2 Market Entropy
4.2.1 Global Sarcopenia Treatment Market Companies with Area Served
4.2.2 Products Offerings Global Sarcopenia Treatment Market
5 COVID-19 Impact Analysis and Outlook Scenarios
5.1.1 Covid-19 Impact Analysis
5.1.2 Post-COVID-19 Scenario- Low Growth Case
5.1.3 Post-COVID-19 Scenario- Reference Growth Case
5.1.4 Post-COVID-19 Scenario- Low Growth Case
6 Global Sarcopenia Treatment Market Trends
6.1 Global Sarcopenia Treatment Revenue (USD Million) and CAGR (%) by Type (2018-2030)
6.2 Global Sarcopenia Treatment Revenue (USD Million) and CAGR (%) by Applications (2018-2030)
6.3 Global Sarcopenia Treatment Revenue (USD Million) and CAGR (%) by Regions (2018-2030)
7 Global Sarcopenia Treatment Market Revenue (USD Million) by Type, and Applications (2018-2022)
7.1 Global Sarcopenia Treatment Revenue (USD Million) by Type (2018-2022)
7.1.1 Global Sarcopenia Treatment Revenue (USD Million), Market Share (%) by Type (2018-2022)
7.2 Global Sarcopenia Treatment Revenue (USD Million) by Applications (2018-2022)
7.2.1 Global Sarcopenia Treatment Revenue (USD Million), Market Share (%) by Applications (2018-2022)
8 Global Sarcopenia Treatment Development Regional Status and Outlook
8.1 Global Sarcopenia Treatment Revenue (USD Million) By Regions (2018-2022)
8.2 North America Sarcopenia Treatment Revenue (USD Million) by Type, and Application (2018-2022)
8.2.1 North America Sarcopenia Treatment Revenue (USD Million) by Country (2018-2022)
8.2.2 North America Sarcopenia Treatment Revenue (USD Million) by Type (2018-2022)
8.2.3 North America Sarcopenia Treatment Revenue (USD Million) by Applications (2018-2022)
8.3 Europe Sarcopenia Treatment Revenue (USD Million), by Type, and Applications (USD Million) (2018-2022)
8.3.1 Europe Sarcopenia Treatment Revenue (USD Million), by Country (2018-2022)
8.3.2 Europe Sarcopenia Treatment Revenue (USD Million) by Type (2018-2022)
8.3.3 Europe Sarcopenia Treatment Revenue (USD Million) by Applications (2018-2022)
8.4 Asia Pacific Sarcopenia Treatment Revenue (USD Million), and Revenue (USD Million) by Type, and Applications (2018-2022)
8.4.1 Asia Pacific Sarcopenia Treatment Revenue (USD Million) by Country (2018-2022)
8.4.2 Asia Pacific Sarcopenia Treatment Revenue (USD Million) by Type (2018-2022)
8.4.3 Asia Pacific Sarcopenia Treatment Revenue (USD Million) by Applications (2018-2022)
8.5 South America Sarcopenia Treatment Revenue (USD Million), by Type, and Applications (2018-2022)
8.5.1 South America Sarcopenia Treatment Revenue (USD Million), by Country (2018-2022)
8.5.2 South America Sarcopenia Treatment Revenue (USD Million) by Type (2018-2022)
8.5.3 South America Sarcopenia Treatment Revenue (USD Million) by Applications (2018-2022)
8.6 Middle East and Africa Sarcopenia Treatment Revenue (USD Million), by Type, Technology, Application, Thickness (2018-2022)
8.6.1 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) by Country (2018-2022)
8.6.2 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) by Type (2018-2022)
8.6.3 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) by Applications (2018-2022)
9 Company Profiles
10 Global Sarcopenia Treatment Market Revenue (USD Million), by Type, and Applications (2023-2030)
10.1 Global Sarcopenia Treatment Revenue (USD Million) and Market Share (%) by Type (2023-2030)
10.1.1 Global Sarcopenia Treatment Revenue (USD Million), and Market Share (%) by Type (2023-2030)
10.2 Global Sarcopenia Treatment Revenue (USD Million) and Market Share (%) by Applications (2023-2030)
10.2.1 Global Sarcopenia Treatment Revenue (USD Million), and Market Share (%) by Applications (2023-2030)
11 Global Sarcopenia Treatment Development Regional Status and Outlook Forecast
11.1 Global Sarcopenia Treatment Revenue (USD Million) By Regions (2023-2030)
11.2 North America Sarcopenia Treatment Revenue (USD Million) by Type, and Applications (2023-2030)
11.2.1 North America Sarcopenia Treatment Revenue (USD) Million by Country (2023-2030)
11.2.2 North America Sarcopenia Treatment Revenue (USD Million), by Type (2023-2030)
11.2.3 North America Sarcopenia Treatment Revenue (USD Million), Market Share (%) by Applications (2023-2030)
11.3 Europe Sarcopenia Treatment Revenue (USD Million), by Type, and Applications (2023-2030)
11.3.1 Europe Sarcopenia Treatment Revenue (USD Million), by Country (2023-2030)
11.3.2 Europe Sarcopenia Treatment Revenue (USD Million), by Type (2023-2030)
11.3.3 Europe Sarcopenia Treatment Revenue (USD Million), by Applications (2023-2030)
11.4 Asia Pacific Sarcopenia Treatment Revenue (USD Million) by Type, and Applications (2023-2030)
11.4.1 Asia Pacific Sarcopenia Treatment Revenue (USD Million), by Country (2023-2030)
11.4.2 Asia Pacific Sarcopenia Treatment Revenue (USD Million), by Type (2023-2030)
11.4.3 Asia Pacific Sarcopenia Treatment Revenue (USD Million), by Applications (2023-2030)
11.5 South America Sarcopenia Treatment Revenue (USD Million), by Type, and Applications (2023-2030)
11.5.1 South America Sarcopenia Treatment Revenue (USD Million), by Country (2023-2030)
11.5.2 South America Sarcopenia Treatment Revenue (USD Million), by Type (2023-2030)
11.5.3 South America Sarcopenia Treatment Revenue (USD Million), by Applications (2023-2030)
11.6 Middle East and Africa Sarcopenia Treatment Revenue (USD Million), by Type, and Applications (2023-2030)
11.6.1 Middle East and Africa Sarcopenia Treatment Revenue (USD Million), by Region (2023-2030)
11.6.2 Middle East and Africa Sarcopenia Treatment Revenue (USD Million), by Type (2023-2030)
11.6.3 Middle East and Africa Sarcopenia Treatment Revenue (USD Million), by Applications (2023-2030)
12 Methodology and Data Sources
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Sources
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Disclaimer
List Of Tables
Table 1 Market Segmentation Analysis
Table 2 Global Sarcopenia Treatment Market Companies with Areas Served
Table 3 Products Offerings Global Sarcopenia Treatment Market
Table 4 Low Growth Scenario Forecasts
Table 5 Reference Case Growth Scenario
Table 6 High Growth Case Scenario
Table 7 Global Sarcopenia Treatment Revenue (USD Million) And CAGR (%) By Type (2018-2030)
Table 8 Global Sarcopenia Treatment Revenue (USD Million) And CAGR (%) By Applications (2018-2030)
Table 9 Global Sarcopenia Treatment Revenue (USD Million) And CAGR (%) By Regions (2018-2030)
Table 10 Global Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Table 11 Global Sarcopenia Treatment Revenue Market Share (%) By Type (2018-2022)
Table 12 Global Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Table 13 Global Sarcopenia Treatment Revenue Market Share (%) By Applications (2018-2022)
Table 14 Global Sarcopenia Treatment Market Revenue (USD Million) By Regions (2018-2022)
Table 15 Global Sarcopenia Treatment Market Share (%) By Regions (2018-2022)
Table 16 North America Sarcopenia Treatment Revenue (USD Million) By Country (2018-2022)
Table 17 North America Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Table 18 North America Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Table 19 Europe Sarcopenia Treatment Revenue (USD Million) By Country (2018-2022)
Table 20 Europe Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Table 21 Europe Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Table 22 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Country (2018-2022)
Table 23 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Table 24 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Table 25 South America Sarcopenia Treatment Revenue (USD Million) By Country (2018-2022)
Table 26 South America Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Table 27 South America Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Table 28 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Region (2018-2022)
Table 29 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Table 30 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Table 31 Financial Analysis
Table 32 Global Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Table 33 Global Sarcopenia Treatment Revenue Market Share (%) By Type (2023-2030)
Table 34 Global Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Table 35 Global Sarcopenia Treatment Revenue Market Share (%) By Applications (2023-2030)
Table 36 Global Sarcopenia Treatment Market Revenue (USD Million), And Revenue (USD Million) By Regions (2023-2030)
Table 37 North America Sarcopenia Treatment Revenue (USD)By Country (2023-2030)
Table 38 North America Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Table 39 North America Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Table 40 Europe Sarcopenia Treatment Revenue (USD Million) By Country (2023-2030)
Table 41 Europe Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Table 42 Europe Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Table 43 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Country (2023-2030)
Table 44 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Table 45 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Table 46 South America Sarcopenia Treatment Revenue (USD Million) By Country (2023-2030)
Table 47 South America Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Table 48 South America Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Table 49 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Region (2023-2030)
Table 50 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Region (2023-2030)
Table 51 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Table 52 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Table 53 Research Programs/Design for This Report
Table 54 Key Data Information from Secondary Sources
Table 55 Key Data Information from Primary Sources
List Of Figures
Figure 1 Market Scope
Figure 2 Porter’s Five Forces
Figure 3 Global Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Figure 4 Global Sarcopenia Treatment Revenue Market Share (%) By Type (2022)
Figure 5 Global Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Figure 6 Global Sarcopenia Treatment Revenue Market Share (%) By Applications (2022)
Figure 7 Global Sarcopenia Treatment Market Revenue (USD Million) By Regions (2018-2022)
Figure 8 Global Sarcopenia Treatment Market Share (%) By Regions (2022)
Figure 9 North America Sarcopenia Treatment Revenue (USD Million) By Country (2018-2022)
Figure 10 North America Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Figure 11 North America Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Figure 12 Europe Sarcopenia Treatment Revenue (USD Million) By Country (2018-2022)
Figure 13 Europe Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Figure 14 Europe Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Figure 15 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Country (2018-2022)
Figure 16 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Figure 17 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Figure 18 South America Sarcopenia Treatment Revenue (USD Million) By Country (2018-2022)
Figure 19 South America Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Figure 20 South America Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Figure 21 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Region (2018-2022)
Figure 22 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Type (2018-2022)
Figure 23 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Applications (2018-2022)
Figure 24 Global Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Figure 25 Global Sarcopenia Treatment Revenue Market Share (%) By Type (2030)
Figure 26 Global Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Figure 27 Global Sarcopenia Treatment Revenue Market Share (%) By Applications (2030)
Figure 28 Global Sarcopenia Treatment Market Revenue (USD Million) By Regions (2023-2030)
Figure 29 North America Sarcopenia Treatment Revenue (USD Million) By Country (2023-2030)
Figure 30 North America Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Figure 31 North America Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Figure 32 Europe Sarcopenia Treatment Revenue (USD Million) By Country (2023-2030)
Figure 33 Europe Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Figure 34 Europe Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Figure 35 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Country (2023-2030)
Figure 36 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Figure 37 Asia Pacific Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Figure 38 South America Sarcopenia Treatment Revenue (USD Million) By Country (2023-2030)
Figure 39 South America Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Figure 40 South America Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Figure 41 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Region (2023-2030)
Figure 42 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Region (2023-2030)
Figure 43 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Type (2023-2030)
Figure 44 Middle East and Africa Sarcopenia Treatment Revenue (USD Million) By Applications (2023-2030)
Figure 45 Bottom-Up and Top-Down Approaches For This Report
Figure 46 Data Triangulation
Market Segmentation
By Type
By Sales Channel
By Region
The global Sarcopenia Treatment market is estimated to be $3.2 billion in 2023.
The market is poised to register 7.04% growth over the forecast period from 2023 to 2030.
Abbott Laboratories, Amway Corporation, Bayer AG, GlaxoSmithKline Plc, Pfizer Inc, Nestle Health Science, Novartis AG, Sanofi Inc, Zydus Cadila, F-Hoffmann La-Roche
Vitamin D & Calcium Supplements, Online Pharmacies, and Asia Pacific are the fastest-growing segments in the market.